Basecamp Wealth Advisors’s Gossamer Bio GOSS Stock Holding History

Basecamp Wealth Advisors’s Portfolio GOSS Stock Details GOSS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$224	Sell	1,359 -553	-29%	-$154	﹤0.01%	1734
2026 Q1	$628	Buy	+1,912	New	+$3K	﹤0.01%	1663

Other funds holding GOSS

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

DIG

DeepCurrents Investment Group New York $3.3B AUM 12.57% 1-Year Est. Return

CCM

Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Basecamp Wealth Advisors's GOSS Position: Q2 2026 in Review

Basecamp Wealth Advisors reduced its Gossamer Bio (GOSS) stake by 29% in Q2 2026, selling an estimated $154 and leaving 1,359 shares worth $224. The position accounts for ﹤0.01% of the portfolio, ranked #1734.

Basecamp Wealth Advisors first reported a position in GOSS in Q1 2026 and has held it in 2 quarters since. The position peaked at $628 in Q1 2026. 170 funds tracked by Wall St. Rank hold GOSS as of Q2 2026.

Basecamp Wealth Advisors held 1,359 shares of Gossamer Bio worth $224 as of Q2 2026.
Basecamp Wealth Advisors sold 553 Gossamer Bio shares in Q2 2026, an estimated $154.
Gossamer Bio made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #1734 holding.
Basecamp Wealth Advisors first reported a position in Gossamer Bio in Q1 2026 and has held it in 2 quarters since.
Basecamp Wealth Advisors's Gossamer Bio position peaked at $628 in Q1 2026.
170 funds tracked by Wall St. Rank held Gossamer Bio as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.